The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study
Abstract
Background For the growing numbers of obese elderly with diabetes, the glucagon-like peptide-1 (GLP-1) receptor analogue (liraglutide) appears a safe way to promote and maintain substantial weight loss. Given this background, the aim of this study was to assess the effect of the liraglutide treatment, at doses up to 3.0 mg per day, on the body composition, focusing on sarcopenia, in overweight and obese elderly with type 2 diabetes mellitus (T2DM).Methods A perspective study was carried out in overweight and obese T2DM patients with HbA1c equal to 7.0 % (53 mmol/mol) ~10.0 % (86), under 3-month treatment (at least) of maximal dose of metformin at stable regime, and additional liraglutide at doses up to 3.0 mg per day. Body composition markers such as skeletal muscle index (SMI), android and gynoid fat mass, and arms and legs fat free mass, was measured by dual-energy X-ray densitometry (DXA) at baseline and after 24 weeks of liraglutide treatment. Glucose control was also carried out by glucose and HbA1c.Results Nine subjects (male/female 6/3, mean age 68.22 ± 3.86 years, BMI 32.34 ± 4.89 kg/m 2) were evaluated. We noted a median decrease in BMI (-0.78 kg/m 2), weight (-2000 g), fat mass (-1498 g) and android fat (-0.9 %), and a increase in SMI (+0.03 kg/m 2) from baseline. Glycemic control also improved, with a median change HbA1c of -0.80 %.Conclusions Twenty-four weeks of liraglutide treatment was associated with reductions in fat mass and android fat. In addition, in order to prevent sarcopenia, it preserved the muscular tropism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In nine older adults prescribed liraglutide, a weight decrease of 2.0 kg (−1.5 kg fat mass and −0.9% android fat) was observed, with a marginal improvement of 0.03 kg/m2 in skeletal muscle index (absolute muscle mass normalized by height squared)381.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [381]
In the citing paper
“a case series by Perna et al. involving sedentary overweight and obese older adults with T2DM (n = 9) demonstrated reduced fat mass and improved SMI after 24 weeks of treatment [50].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [50]
In the citing paper
“In the Liraglutide Effect and Action in Diabetes trial (LEAD-3), GLP-1RA liraglutide treatment significantly reduced body fat, but there was no significant change in lean body mass.11”
From GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway (2023) · cites this paper as [12]
In the citing paper
“Only one study focused on the pharmacological treatment by liraglutide, a glucagon-like peptide-1 receptor agonist, reporting preserved muscle mass despite loss of body fat [48].”
From Identification of factors associated with sarcopenic obesity development: Literature review and expert panel voting (2024) · cites this paper as [48]
Citations
Cites
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
The physical activity scale for the elderly (PASE): Development and evaluation
Washburn, R. A., Smith, K. W., Jette, A. M., & Janney, C. A. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90053-4 · Cited by 3,177 · cited 1×
“It uses frequency, duration, and intensity level of activity over the previous week to assign a score, ranging from 0 to 793, with higher scores indicating greater physical activity [16].”
BackgroundSkeletal Muscle Cutpoints Associated with Elevated Physical Disability Risk in Older Men and Women
Janssen, I. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh058 · Cited by 1,190
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Also, thyroid tumors were reported to be more common in rodent toxicology studies with the GLP-1 agonist liraglutide, although the relevance of this in humans has been questioned [30].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Nikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y.-T., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 514
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Research works printed but not linked: 1
- Green CJ, Henriksen TI, Pedersen BK et al (2012) Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PloS One 7:e44284 · DOI · Paper page
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
“Although, as said above, weight loss induced by GLP-1 RAs comes mainly from reductions in fat mass rather than lean mass, nutritional advice and exercise programmes to achieve muscle strengthening are recommended to minimize sarcopenic risk [74].”
BackgroundSargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
McCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I. (2020) · Diabetologia · doi:10.1007/s00125-019-05065-8 · Cited by 184
“While indirect comparisons across clinical trials should be interpreted with caution, given the heterogeneity of the study populations, these findings suggest that body composition changes with semaglutide are consistent with those in previous studies of other GLP-1RAs.”
BackgroundResultInfluential
Metadata
- Authors
- Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M.
- Affiliations
- University of Pavia (IT)
- Corresponding author
- Perna, Simone
- Venue
- Aging Clinical and Experimental Research
- Published
- 2016-01-09
- Volume
- 28
- Issue
- 6
- Pages
- 1251-1257
- ISSN
- 1594-0667 (ISSN-L)
- 1720-8319
- OpenAlex
- W2236655565
- Cited by
- 125
- References
- 31
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 26 · 2023: 16 · 2022: 14 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 1 · 2016: 1
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Aging Clinical and Experimental Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, sarcopenia prevention, type 2 diabetes, weight loss, body composition, skeletal muscle index, android fat, gynoid fat, fat-free mass, glycemic control, HbA1c, metformin
- MeSH terms
- Liraglutide, Aged, Body Composition, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Prospective Studies, Biomarkers, Overweight, Glucagon-Like Peptide 1, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. https://app.cochat.ai/papers/10.1007/s40520-015-0525-y
- The paper
- Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016). Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-015-0525-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.